The transcription factor p53 is a tumor suppressor. As such, the P53 gene is frequently altered in human cancers. However, over 80% of the P53 mutations found in human cancers are missense mutations that lead to expression of mutant proteins that not only lack p53 transcriptional activity but exhibit new functions as well. Recent studies show that restoration of p53 expression leads to tumor regression in mice carrying p53 deletions. However, the therapeutic efficacy of restoring p53 expression in tumors containing p53 missense mutations has not been evaluated. Here we demonstrate that restoring wild-type p53 expression halted tumor growth in mice inheriting a p53 R172H missense mutation that is equivalent to a P53 missense mutation detected in approximately 6% of human cancers. However, it did not lead to tumor regression, as was observed in mice lacking p53. We further showed that the dominant-negative effect of the mutant p53 encoded by p53 R172H dampened the activity of the restored wild-type p53. We therefore conclude that in a mutant p53 background, p53 restoration has the therapeutic potential to suppress tumor progression. Our findings support using p53 restoration as a strategy to treat human cancers with P53 missense mutations and provide direction for optimizing p53 restoration in cancer therapy.
Introduction
The tumor suppressor p53 is a transcription factor. Upon activation by signals, such as DNA damage, oncogenic stimuli, and hypoxia, wild-type p53 activates the transcription of genes involved in apoptosis, cell cycle arrest, differentiation, and senescence (1, 2) . These potent antitumor activities prevent cells with aberrant growth signals from proliferating. Approximately, half of human cancers have P53 gene alterations that result in loss of p53 activity. While a few of these alterations are P53-null mutations, over 80% are P53 missense mutations that lead to expression of mutant p53 proteins (3, 4) . Many p53 missense mutants lack p53 transcriptional activity and show gain-of-function activities.
In particular, the arginine-to-histidine mutation at codon 175 of the P53 gene (corresponding to p53 R172H in mice) occurs in about 6% of human cancers (5) . The p53 R172H mutation has gain-of-function properties, manifested as a tumor metastasis phenotype in p53 R172H heterozygous mice that is lacking in p53 +/-mice (6, 7) . Another property of the p53R172H mutant is its dominant-negative effect that silences wild-type p53 under some circumstances (8) . Thus, for example, in response to γ-irradiation, mutant p53R172H inactivates wild-type p53 activities (9) . Additionally, mutant p53 binds and suppresses the activities of the related proteins, p63 and p73 (7) . However, the p53 R172H heterozygous mice that express equal amounts of wild-type and mutant p53 have survival curves identical to those of p53 +/-mice, indicating that mutant p53 does not inactivate wild-type p53 (8) . One possible explanation for this discrepancy is that once stabilized, mutant p53 has a longer half-life than wild-type p53 and thus overwhelms wild-type p53 function (10) .
Since p53 inactivation is common in human cancers, p53 restoration offers a very promising therapy for cancer treatment. The replenished wild-type p53, if properly activated, confers cell cycle arrest and cell death, both of which represent effective mechanisms of tumor suppression (11) . Recent mouse tumor studies have provided direct evidence to support the rationale for using p53 restoration in cancer therapy. Three research groups independently generated genetically modified mice that allowed restoration of wild-type p53 expression in tumors lacking p53 (12) (13) (14) . The lymphomas, sarcomas, and carcinomas that developed in these mice regressed after p53 restoration by initiating apoptosis or senescence in a tumor-specific manner. While exciting, these studies do not address the effects of p53 restoration in tumors with mutant p53, as would be the case in many human tumors. The activity of the restored wild-type p53 might be compromised by the stabilized mutant p53 in tumors. We hypothesized that in a mutant p53 background, the restored wild-type p53 may be less effective as a tumor suppressor.
The purpose of this study was to evaluate the therapeutic efficacy of p53 restoration in spontaneous mouse tumors with mutant p53. We generated a mouse model that allowed wildtype p53 restoration in vivo and demonstrated that p53 restoration led to tumor regression in mice lacking p53, as previously published (13) . More importantly, p53 restoration halted tumor growth in mice containing the p53 R172H mutation, although it did not lead to tumor regression. We further showed that the dominant-negative effect of the p53R172H mutant dampened the activity of the restored wild-type p53. Our results support the use of p53 restoration in the treatment of human cancers with p53 missense mutations.
Results
Generation of a latent p53 allele. We generated a latent p53 allele using gene targeting. This allele, designated the p53 neo allele, contained a floxed PGKneo cassette that was inserted into intron 4 of the p53 locus ( Figure 1A ). p53 was confirmed to be wild type by sequencing (data not shown). Southern blot analysis was used to verify correct targeting and germline transmission of the p53 neo allele in mice ( Figure 1B ). The PGKneo cassette was removed from the p53 neo allele by Cre recombination, and the resultant allele was designated p53 Δneo ( Figure 1A ). The p53 expression from the p53 neo and p53 Δneo alleles was examined in mouse embryonic fibroblasts (MEFs) ( Figure 1C ). After doxorubicin treatment, the levels of p53 expression in p53 neo/-and p53 neo/neo MEFs were 7.4% and 16.1%, respectively, of the level of p53 expression in p53 +/+ MEFs ( Figure 1C ), while p53 +/-MEFs were 50.5% of the level of p53 expression in p53 +/+ MEFs (Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI44504DS1). p53 neo/-and p53 neo/neo MEFs activated p21, a direct target of p53, at 33.7% and 68.9% that of p53 +/+ MEFs, respectively. Equivalent p53 and p21 protein levels were observed in p53 Δneo/Δneo and p53 +/+ MEFs. Thus, the PGKneo cassette downmodulated endogenous p53 expression from the p53 neo allele, and deletion of PGKneo allowed restoration of normal p53 levels.
Transformed mouse 3T3 cell double minute 2 (Mdm2) is a potent p53 inhibitor, and the embryonic lethality of Mdm2-null mice is rescued by concomitant deletion of p53 (15, 16) . Thus, the Mdm2-null phenotype offers a unique opportunity to examine p53 activity in vivo. To examine whether the p53 neo allele was functionally null, we crossed p53 -/-Mdm2 -/-mice with p53 neo/neo Mdm2 +/-mice. Although p53 neo/-Mdm2 -/-and p53 neo/-Mdm2 +/-mice were born at the correct ratios, the p53 neo/-Mdm2 -/-mice were smaller and less mobile than their p53 neo/-Mdm2 +/-siblings and died by weaning age (Supplemental Figure 2 and Supplemental Table 1 ). The p53 neo/neo genotype did not rescue the embryonic lethality of Mdm2 -/-mice (data not shown). Taken together, these data argue that the p53 neo allele retained some wild-type activity and was thus hypomorphic.
Figure 1
Generation of a latent p53 neo allele. (A) Targeting strategy to generate p53 neo and p53 Δneo alleles. The p53 neo allele, with insertion of the PGKneo gene flanked by loxP sites (triangles) in intron 4 (introns are represented by lines and exons by rectangles), was generated by homologous recombination. The p53 Δneo allele was generated by crossing p53 neo/+ mice with ZP3-Cre transgenic mice. (B) Southern blot analysis of tail DNA samples of p53 wild-type (+/+), p53 neo/+ (neo/+), and p53 neo/neo (neo/neo) mice after digestion with EcoRI and SalI. (C) Western blot analysis of p53 and p21 expression in doxorubicin-treated MEFs with p53 -/-(-/-), p53 neo/-(neo/-), p53 neo/neo , p53 Δneo/Δneo (Δ/Δ), and p53 wild type genotypes. Levels of p53 and p21 were normalized to actin. The numbers under lanes indicate the p53 and p21 protein levels (percentages) relative to those for wild-type mice. (D) Survival curves of p53 -/-(n = 35), p53 R172H/-(H/-, n = 34), p53 neo/R172H (neo/H, n = 40), p53 neo/-(n = 37), p53 neo/neo (n = 30), p53 +/-(+/-, n = 40), and p53 Δneo/Δneo (n = 38) mice. In crosses with p53 R172H/R172H mice, the p53 neo/R172H Mdm2 -/-mice were completely rescued (Supplemental Figure 2 and Supplemental Table 1 ), indicating that the p53 R172H allele masked the wild-type activity of the p53 neo allele in vivo. Analysis of survival and tumorigenesis. To monitor survival and tumor development, we generated cohorts of p53 mutant mice in the C57BL/6 background. Compared with p53 -/-and p53 +/-mice with median survival time of 160 and 578 days, respectively, p53 neo/-and p53 neo/neo mice had median survival times of 251 and 395 days, respectively ( Figure 1D ). This gene-dosage effect on survival confirmed that the p53 neo allele was hypomorphic. In contrast, the survival curve of p53 neo/R172H mice was identical to those of p53 -/-and p53 R172H/-mice ( Figure 1D ). Therefore, in p53 neo/R172H mice, the presence of p53 R172H eliminated the potential increase in survival allowed by the p53 neo allele. The p53 Δneo/Δneo mice survived normally, with no tumor development by 25 months, similar to wild-type mice. Most p53 neo/-, p53 neo/neo , and p53 neo/R172H mice died of tumor development. The most common tumor types in these mice were lymphomas and sarcomas (Table 1) . p53 neo/R172H mice developed 59.6% lymphomas and 36.5% sarcomas, which was similar to the 56% and 40% observed frequency, respectively, in p53 -/-mice (7). In contrast, the p53 neo/-and p53 neo/neo mice showed an increased frequency of sarcomas (61.4% and 61.3%, respectively) with a decreased frequency of lymphoma development (34.1% and 32.2%, respectively), as compared with that in p53 -/-mice. Thus, expression of a small amount of wildtype p53 from the p53 neo allele led to a shift in tumor spectrum with an increase in the number of sarcomas, except in combination with the p53 R172H allele.
p53 restoration in vivo. To temporally restore the p53 gene in vivo, we generated p53 neo/-Cre-ER TM and p53 neo/R172H Cre-ER TM mice. The Cre-ER TM transgene constitutively expresses a Cre-ER fusion protein that becomes active only after tamoxifen exposure (17) . Six-week-old p53 neo/-Cre-ER TM mice were treated with tamoxifen by weekly intraperitoneal injections. Southern blot analysis confirmed the conversion of the p53 neo allele to p53 Δneo in various tissues of mice treated for 1 or 3 weeks (Supplemental Figure 3) . To determine how efficient p53 restoration was in activation of p53, we performed immunohistochemistry experiments with p53 and cleaved caspase-3 antibodies after Cre-mediated recombination, followed by whole-body γ-irradiation ( Figure 2 ). Increased p53 and cleaved caspase-3 staining were observed in the spleens and thymi of irradiated, tamoxifen-treated p53 neo/-Cre-ER TM mice compared with that in mice of the same genotype without tamoxifen treatment. As a control, irradiated p53 +/-mice showed extensive p53 activity ( Figure 2 and Supplemental Figure 4 ). These data demonstrated that tamoxifen treatment worked effectively to trigger p53 restoration in vivo.
Tumor suppression after p53 restoration. To characterize tumor response after p53 restoration, we established cohorts of p53 neo/R172H and p53 neo/-mice with and without Cre-ER TM . These mice underwent MRI periodically to screen for spontaneous tumor development. Upon detection of a tumor, mice were treated 4 times weekly with tamoxifen by intraperitoneal injection. If a mouse survived for 4 weeks, it was then imaged again. Otherwise, a second image was taken before the mouse was euthanized. Tumor volumes were calculated from a sequence of MRI images, and the change in tumor volume was calculated as a percentage of the original tumor volume at the time of detection. In the p53 neo/-Cre-ER TM mice, tamoxifen treatment caused tumor regression, as previously reported for other p53 restoration models (12) (13) (14) . All 8 tamoxifen-treated p53 neo/-Cre-ER TM mice (4 lymphomas and 4 sarcomas) showed tumor regression, ranging from 18.3% to 98.9% ( Figure 3 , A and D, and Supplemental Table 2 ). We confirmed that this effect was caused by p53 restoration, not tamoxifen itself, as control p53 neo/-mice (3 lymphomas and 5 sarcomas) showed rapid progression within 3 weeks despite tamoxifen treatment ( Figure 3D and Supplemental Table 2 ). Tumor volumes increased from as little as 67.3% to as much as 387.9%.
In p53 neo/R172H Cre-ER TM mice that express mutant p53, p53 restoration did not cause tumor regression but halted tumor growth. All 8 p53 neo/R172H Cre-ER TM tumors (5 lymphomas and 3 sarcomas) showed little or no growth (<45%) after weekly injections of tamoxifen ( Figure 3 , B and D, and Supplemental Table 2 ). In contrast, the p53 neo/R172H control tumors (5 lymphomas and 3 sarcomas) showed rapid growth, with tumor volumes ranging from 145.3% to 1,036.4% within 2 weeks ( Figure 3 , C and D, and Supplemental Table 2 ). Moreover, after tamoxifen treatment, 62.5% of p53 neo/R172H Cre-ER TM mice and 75.0% of p53 neo/-Cre-ER TM mice survived to the fourth week, whereas all p53 neo/R172H and p53 neo/-control mice died within 3 weeks ( Figure 3E ). This effect on survival occurred regardless of tumor size at the onset of treatment.
To exclude the possibility that the phenotypic differences observed in p53 neo/R172H Cre-ER TM and p53 neo/-Cre-ER TM mice might simply be explained as differences in efficiency of p53 neo recombination, we examined the levels of the remaining p53 neo allele in tumors after p53 neo recombination, using a genomic DNA realtime PCR strategy. Since these tumors contained 1 p53 neo allele originally, the measurement of the remaining level of the p53 neo allele after tamoxifen treatment will denote the efficiency of the p53 neo recombination in these tumors. The average levels of p53 neo remaining in the p53 neo/-Cre-ER TM and p53 neo/R172H Cre-ER TM lymphomas after tamoxifen treatment were similar (52.1% and 53.5%, respectively; P = 0.87), suggesting no significant difference in p53 neo recombination in these tumors (Supplemental Figure 5) . Another concern is that the presence of the Cre-ER TM transgene may promote tumorigenesis in mice. We therefore compared the survival of the p53 neo/R172H and the p53 neo/R172H Cre-ER TM mice without treatment. The overlapping survival curves between these 2 cohorts suggest that the Cre-ER TM transgene did not contribute to tumorigenesis in the p53 neo/R172H Cre-ER TM mice (Supplemental Figure 6) .
Apoptosis and senescence contribute to tumor suppression upon p53 restoration. To determine the mechanism(s) responsible for tumor suppression, we compared tumor response with and without p53 restoration. After 4 weekly tamoxifen injections, apoptosis was elevated in both p53 neo/-Cre-ER TM ( Figure 7) . Remarkably, in addition to apoptosis, 3 out of the 5 p53 neo/R172H Cre-ER TM lymphomas, but none of the p53 neo/-Cre-ER TM lymphomas, showed induction of senescence, as detected by senescence-associated β-galactosidase (SA-β-gal) activity ( Figure 4A ). This phenotype was also observed in lymphomas that were collected 3 days after a single dose of tamoxifen. Four out of these six p53 neo/R172H Cre-ER TM lymphomas showed induction of senescence, as detected by SA-β-gal assays and immunohistochemistry with senescence markers PML and DcR2 (Supplemental Figure 8) . Therefore, the restored p53 activated both apoptosis and senescence programs in lymphomas from p53 neo/R172H Cre-ER TM mice. Additionally, immunohistochemistry revealed lower levels of proliferation markers Ki-67 and phospho-histone 3 in Cre-ER TM -positive lymphomas than in Cre-ER TM -negative controls ( Figure 4 , A and B), indicating that p53-induced apoptosis and/or senescence decreased tumor cell proliferation.
In p53 neo/-Cre-ER TM (3 samples) and p53 neo/R172H Cre-ER TM (3 samples) angiosarcomas, the major tumor response after tamoxifen treatment was senescence, as detected by SA-β-gal staining ( Figure 5A ). However, in other sarcomas, such as giant-cell sarcoma and spindle-cell sarcoma, both apoptosis and senescence were detected (Supplemental Figure 9 and data not shown). The tamoxifentreated p53 neo/-Cre-ER TM angiosarcomas also showed less tumor cell proliferation than the Cre-ER TM -negative control tumors (7 samples) ( Figure 5, A and B) . Thus, the p53-induced antitumor activities suppressed tumor growth in different tumors by different and sometimes overlapping mechanisms. We next addressed the role of the innate immune system in tumors after p53 reactivation in angiosarcomas. Inflammatory cell infiltration in tumors of different genotypes was determined by counting the number of polymorphonuclear cells and lymphocytes in areas devoid of focal inflammatory aggregates. p53 neo/-and p53 neo/R172H tumors harbored a slightly higher (although insignificant) number of interstitial inflammatory cells compared with that in their respective p53 neo/-Cre-ER TM and p53 neo/R172H Cre-ER TM tumor counterparts (Supplemental Figure 10) . Histological analysis also revealed that p53 neo/-and p53 neo/R172H tumors had occasional focal inflammatory aggregates that were rare or absent in p53 neo/-Cre-ER TM and p53 neo/R172H Cre-ER TM tumors. p53 response upon restoration in tumors. To monitor p53 reactivation in tumors upon initial tamoxifen treatment, we performed biopsies to harvest tumor tissue from mice bearing visible subcutaneous tumors. We compared the effect of wild-type p53 restoration in tumors from p53 neo/-Cre-ER TM mice with those from p53 neo/R172H Cre-ER TM mice. In p53 neo/-Cre-ER TM spindle-cell sarcomas (2 samples), p53 and p21 levels were elevated as early as 1 day after tamoxifen treatment. The highest levels of p53-induced apoptosis were observed 3 days after tamoxifen treatment ( Figure 6 , A and C). In p53 neo/R172H Cre-ER TM spindle-cell sarcomas (2 samples), immunohistochemistry revealed increased p53 levels 1 day after tamoxifen treatment (we cannot distinguish between wild-type and mutant p53 staining). Moreover, in the same tumors, p21 levels were elevated after tamoxifen treatment, suggesting wild-type p53 activity. Apoptosis was also induced in these tumors but to a lesser degree than in p53 neo/-Cre-ER TM tumors ( Figure 6 , B and C). In a p53 neo/-Cre-ER TM angiosarcoma, the tumor showed elevated p53 and p21 levels when examined at day 3 after tamoxifen treatment, and the restored p53 also activated senescence as revealed by SA-β-gal staining (Supplemental Figure 11) . In a p53 neo/R172H Cre-ER TM angiosarcoma, p53 and p21 were also elevated 3 days after tamoxifen treatment. However, fewer cells were senescent upon p53 restoration in the p53 neo/R172H Cre-ER TM angiosarcoma than in the p53 neo/-Cre-ER TM angiosarcoma (Supplemental Figure 11) . These data suggest that the restored wild-type p53 was activated in tumors after the initial tamoxifen injection and that p53 restoration led to lower level of p53 activation in the p53 neo/R172H Cre-ER TM tumors than that in the p53 neo/-Cre-ER TM tumors.
p53R172H dampens the activity of the restored wild-type p53. To explore the antagonizing effect of p53R172H on the restored wildtype p53, we collected angiosarcomas from the p53 neo/R172H Cre-ER TM and p53 neo/-Cre-ER TM mice 3 days after tamoxifen treatment. First, we compared recombination at the p53 neo allele in these tumors using genomic DNA and real-time PCR. Recombination of p53 neo was comparable in the p53 neo/R172H Cre-ER TM and the p53 neo/-Cre-ER TM tumors (P = 0.97; Supplemental Figure 12 ). Despite similar recombination frequencies, the p53 neo/-Cre-ER TM angiosarcomas showed more cells with a senescent phenotype than the p53 neo/R172H Cre-ER TM angiosarcomas, as detected by SA-β-gal assays and immunohistochemistry of senescence markers p16 and Dec1 (P = 0.019, P = 0.032, and P = 0.043, respectively; Figure 7, A and B) . Expression of p21 and cyclin G1 (Ccng1), 2 p53 target genes, was also enhanced in the p53 neo/-Cre-ER TM angiosarcomas relative to that in the p53 neo/R172H Cre-ER TM angiosarcomas (P = 0.0033 and P = 0.030, respectively; Figure 7 , C and D). We also compared levels of p53 activation in isogenic p53 neo/R172H Cre-ER TM and p53 neo/-Cre-ER TM MEFs treated with 4-hydroxy-tamoxifen (to recombine the p53 neo allele) and with doxorubicin (to activate p53). Cells from both genotypes had similar p53 neo recombination frequencies, but p53 neo/-Cre-ER TM MEFs have a higher level of p53 target gene expression (p21, Ccng1, and p53 up-regulated modulator of apoptosis [puma] ) than p53 neo/R172H Cre-ER TM MEFs (Supplemental Figure 13) . In both tumors and MEFs, p53 levels were also upregulated, although we cannot distinguish between wild-type and mutant p53 proteins using Western blots ( Figure 7D and Supplemental Figure 13 ). To determine whether the p53R172H mutant binds to wild-type p53, we transfected His-tagged wild-type p53 in p53 neo/-Cre-ER TM and p53 neo/R172H Cre-ER TM sarcoma tumor cell lines that were established from untreated Positive cells were counted in 4 random fields (original magnification, ×40) and presented as the mean ± SEM. Statistical significance between tumors with different genotypes was calculated using the t test, and the P value is less than 0.05 for p21 and cleaved caspase-3 at day 3 and day 5.
mice and then immunoprecipitated the p53 complex with the mutant p53-specific antibody, PAb240, that recognizes the mutant p53 conformation. As shown in Supplemental Figure  14 , the p53R172H mutant bound His-tagged wild-type p53. To examine direct p53 binding to p21 and puma promoters, we performed ChIP experiments in the above p53 neo/R172H Cre-ER TM and p53 neo/-Cre-ER TM sarcoma tumor cell lines. After 4-hydroxytamoxifen treatment, both cell lines showed similar p53 neo recombination frequencies ( Figure 7E ). Reproducibly, p53 bound to the p21 but not to the puma promoter ( Figure 7F ). More importantly, the p53 neo/-Cre-ER TM tumor cells showed more p53 binding to the p21 promoter than p53 neo/R172H Cre-ER TM tumor cells ( Figure 7F ). These data were consistent with increased expression of p21 but not puma ( Figure 7G ). Thus, p53R172H dampened the activity of restored wild-type p53 through inhibition of wild-type p53 transcriptional activity.
Discussion
In this study, we engineered a mouse model in which we restored wild-type p53 in tumors that contained a p53 missense mutation, since most human cancers harbor P53 missense mutations with gain-of-function and dominant-negative activity. In these mice, p53 restoration led to delayed tumor growth. The delay in tumor growth predicts a positive therapeutic effect of p53 restoration in p53 mutant tumors.
Tumor regression in our p53 neo/-Cre-ER TM mice was consistent with that in previous reports, even though only 1 copy of the wildtype p53 allele was restored in our mice (13) . The restored wildtype p53 induced apoptosis and senescence in tumors, indicating that the p53 pathway is reactivated in tumors and that absence of p53 is required for maintenance of the tumor phenotype. We also observed that tumor response to p53 restoration was tumor-type specific. p53 restoration mainly induced apoptosis in lymphomas and senescence in angiosarcomas. However, p53 restoration induced both apoptosis and senescence in giant-cell and spindlecell sarcomas. An understanding of the mechanisms that trigger apoptosis or senescence should lead to better therapies.
Unlike the tumor regression phenotype observed in p53 neo/-Cre-ER TM mice, we found arrested tumor growth in the p53 neo/R172H Cre-ER TM mice after p53 restoration, suggesting a dominant-negative effect of the p53 R172H mutation in vivo. The dominant-negative effect was first shown in in vitro cotranslation experiments, in which mutant p53 drove wild-type p53 into an inactive conformation after hetero-oligomerization (18) . Hetero-oligomerization prevents wild-type p53 from binding to its target DNA sequence (19, 20) . In the present study, the p53 neo/R172H mice had survival times similar to those of the p53 -/-and p53 R172H/-mice, indicating that the p53 R172H allele completely dominated the hypomorphic p53 neo allele. Therefore, the p53R172H mutant effectively abrogates the activity of the small amount of wild-type p53 expressed by the p53 neo allele but can not completely abolish normal levels of wild-type p53 activity, as indicated by the fact that p53 +/-and p53 +/R172H mice share similar survival curves.
Overexpression of mutant p53 shows a dominant-negative effect in cultured tumor cell lines (21) (22) (23) (24) . Here we demonstrated that the p53R172H mutant partially inhibited the activity of the restored wild-type p53 in tumors. Unlike the short-lived wildtype p53 protein, p53R172H is stabilized and accumulates to a high level in tumors (10) . The stabilized mutant p53 increases the probability that hetero-oligomers form between the wild-type and the mutant p53, which would result in loss of the wild-type p53 activities. However, in our study, the restored wild-type p53 was not overwhelmed, as evidenced by the fact that in p53 R172H tumors, p53 retained some activity. We hypothesize that some wild-type p53 escaped from binding the mutant p53 and formed functional homo-tetramers.
Inactivation of wild-type p53 by the p53R172H mutant reduced levels of p53 activation in tumors after p53 restoration, as shown by the lower levels of apoptosis and senescence in p53 neo/R172H Cre-ER TM tumors than in p53 neo/-Cre-ER TM tumors. Interestingly, we observed senescence in p53 neo/R172H Cre-ER TM lymphomas but not in p53 neo/-Cre-ER TM lymphomas. This may be dose dependent, as stochastic assembly of fewer wild-type p53 tetramers may lead to senescence not apoptosis. In vitro studies suggest that the intracellular level of activated p53 affects promoter binding and transactivation (25, 26) . A high level of active p53 initiates apoptosis because low-affinity p53 binding sites present in promoters of apoptosis-related genes are activated. On the other hand, p53, when present at low levels, binds only high-affinity sites present in promoters of genes involved in cell cycle arrest (27) (28) (29) . Therefore, in p53 neo/-Cre-ER TM lymphomas, the restored wild-type p53, in the absence of mutant p53, insured the activation of apoptosis. However, in p53 neo/R172H Cre-ER TM lymphomas, the decreased level of p53 activation caused by the dominant-negative effect of mutant p53 may have promoted the transactivation of genes involved in cell cycle arrest and senescence.
Our studies have revealed a dosage-dependent effect of p53-induced tumor suppression in vivo. First, the small amount of wild-type p53 expressed by the hypomorphic p53 neo allele delayed tumor onset and resulted in a shift in tumor spectrum toward sarcomas. Second, the decreased level of the functional wild-type p53 in the p53 R172H tumors led to arrested tumor growth but not tumor regression. We therefore speculate that excessive wild-type p53 will increase the level of functional p53 over that of mutant p53. The goal of p53 gene transfer in clinical trials is to achieve overexpression of wild-type p53 in human cancers (30) . Our findings in mice lead us to speculate that this strategy could lead to tumor regression in humans. Likewise, other strategies, such as the use of the chemical drug PRIMA to restore the mutant p53 to a wild-type competent conformation, may synergize with restoration of wildtype p53, leading to tumor regression (31) .
The use of genetically engineered mouse models bypasses some difficulties confronted by clinicians in designing p53 gene therapy. First, p53 restoration in mouse models is a one-hit genetic event that is guaranteed to happen. Second, the wild-type p53 is produced endogenously by a modified p53 locus, ignoring any delivery blockades that hinder P53 gene transfer into tumor cells of human patients. Additionally, some human cancers containing no P53 mutations may tolerate wild-type p53 restoration. These may account for the limited effectiveness of P53 gene therapy that has been thus far realized in clinical trials (32) (33) (34) (35) (36) . Nevertheless, our results, together with those from previous studies, emphasize the potential therapeutic efficacy of p53 restoration in human cancer treatment. Specifically, the most important implication of the current findings is that p53 restoration has therapeutic potential in human cancers with P53 missense mutations, not just loss of P53.
Methods
Mice. The p53 neo allele was generated in our laboratory using the same strategies as we used to generate the p53 R172H allele (also designated p53 R172H ref. 7) , except that no p53 R172H mutation was engineered in the p53 neo allele (7). Chimeric mice carrying the p53 neo allele were generated in Genetically Engineered Mouse Facility of The University of Texas MD Anderson Cancer Center and were crossed with C57BL/6 mice from the National Cancer Institute for more than 5 generations, so that the genetic background of the mice was greater than 95% C57BL/6. The p53 neo/+ mice were crossed with ZP3-Cre transgenic mice to generate p53 Δneo/+ mice. Genotyping was performed by PCR analysis using primers surrounding the loxP site and 1 primer in the neo cassette. Southern blotting. Southern blot analyses were performed as previously described (7). A specific DNA probe spanning exons 3 and 4 was used for hybridization with both the p53 neo and p53 Δneo alleles but not the p53 null allele. The PhosphorImager (Molecular Dynamics) was used to measure radioactive intensity on the membrane used in Southern blotting.
Tamoxifen treatment. Tamoxifen (Sigma-Aldrich) was dissolved in corn oil to a concentration of 30 mg/ml. After tumors were detected, the mice were treated with tamoxifen by intraperitoneal injection at a dose of 3 mg per 40 g of body weight.
MRI analysis. Anesthesia was induced using 5% isoflurane in oxygen and maintained using 1%-3% isoflurane in oxygen. Anesthesia levels were monitored using respiratory bellows in conjunction with a small-animal physiological monitoring system (Small Animal Instruments Inc.). All magnetic resonance images were acquired using a 7T BioSpec small-animal imaging system (Bruker Biospin MRI) and imaging gradients with a 60-mm inside diameter. A linear volume resonator (35-mm inside diameter) was used for signal excitation and detection. Scout images to verify animal positioning were followed by coronal T2-weighted rapid acquisition with relaxation enhancement (RARE) scans (echo time/repetition time, 65 ms/5,000 ms; 40-mm × 30-mm field of view; 256 × 192 voxels image matrix was zero filled to 256 × 256 voxels; 1-mm slice thickness with 0.25 skip; RARE factor 12; 4 averages). Tumor volumes (in cm 3 ) were measured by segmentation of T2-weighted coronal and axial image stacks using ParaVision 4.0 software (Bruker Biospin MRI).
Histology and immunohistochemistry. Normal and tumor mouse tissues were collected and processed for histological analysis as previously described (7) . Fresh tumor biopsy specimens were collected from mice with subcutaneous tumors under anesthesia, using a 1.5-mm biopsy punch (Miltex). Immunohistochemical analyses were performed as previously described (37) on paraffin-embedded sections, using antibodies for p53 ( SA-β-gal assay. Tumor tissues were collected and fixed in 4% paraformaldehyde and then incubated in Hank's buffered salt solution supplemented with 10%, 15%, or 20% of sucrose. Tissues were frozen in Optimal Cutting Temperature compound (OTC) (Sakura Finetek). SA-β-gal staining was performed as previously described on 10-μm frozen sections (38) .
Cell culture and Western blotting. MEFs were generated by collecting embryos at 13.5 days post coitum after crossing mice of the appropriate genotypes. The cell cultures were maintained as previously described (39) . Protein extracts (50 μg) from MEFs or tumor tissues were resolved on SDS-PAGE, transferred to Hybond P membrane (Amersham-Pharmacia), and incubated with primary antibodies for p53 (CM5, Vector Laboratories; 1:500; and FL-393, Santa Cruz Biotechnology Inc.; 1:100), p21 (SX118, BD Pharmingen; 1:500), cyclin G1 (c-18, Santa Cruz Biotechnology Inc.; 1:500), puma (Cell Signaling Technology; 1:1,000), and actin (SigmaAldrich; 1:2,000). After being incubated with horseradish peroxidase-conjugated secondary antibody, the proteins bound to the membrane were visualized using ECL (GE Healthcare). The intensity of the protein bands on the membrane was measured using ImageJ software (http://rsbweb. nih.gov/ij/). As for protein immunoprecipitation, after transfection, a total of 500 μg of cell lysates were incubated with 50 μl of protein A/G agarose beads (Calbiochem) and 5 μg of p53 PAb240 antibody (Ab-3, Calbiochem). The protein complexes were eluted with 50 μl Laemmli sample buffer, resolved on SDS-PAGE, and blotted with p53 and anti-His (Cell Signaling Technology; 1:500) antibodies.
Real-time PCR. Genomic DNAs were extracted from homogenized tumor tissues after proteinase K digestion followed by phenol-chloroform cleanup. Total RNAs were extracted using TRIzol (Ambion). Firststrand cDNAs were synthesized using a kit from GE Healthcare. The Primer Express program (Applied Biosystems) was used to design primer sequences. The primers used for p53 neo amplification were 5′-GCTTGCG-GAACCCTTAATATAACTT-3′ and 5′-GCTGTCCTGGAACTCACTTTG-TAG-3′, spanning the neo cassette and intron 4 of p53 locus. Real-time reverse transcription PCR and the primers for p21, Ccng1, and Gapdh were previously described (40) .
ChIP. ChIP assays were performed as previously described (41) . The antibody used for p53 was CM5 (Vector Laboratories). Sarcoma tumor cell lines were harvested from 150-mm plates after 4-hydroxy-tamoxifen treatment for 1 day. Real-time PCR was performed in a 384-well plate using the ABI Prism 7900HT with 5 μl 2× SYBR Green PCR Master Mix (Applied Biosystems), 1 μl each of 8 μM forward and reverse primers, and 3 μl of the template. Primers used were p21, 5′-GGCCTTCAGGAACAT-GTCTTG-3′ and 5′-ACCACCCTGCACTGAAGCA-3′; puma, 5′-GGACG- GTCGCCTTGCA-3′ and 5′-CAGCCTTAGTCCCAGTGATGAAA-3′; and acetylcholine receptor (AchR), 5′-CCTCCCCCAACTCCACTTTT-3′ and 5′-GGAGGTTGGAGGGAGAAGGA-3′.
Statistics. The Prism 4 program (GraphPad Software) was used to perform statistical analysis. A P value of ≤ 0.05 was considered statistically significant. Kaplan-Meier analyses were performed to compare differences between survival curves, and 2-tailed Student's t test analysis was performed to compare differences between treatment groups or individual mice before and after treatment.
